Patients seropositive to Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (anti-CCP) who were treated with MabThera in combination with methotrexate showed an enhanced response compared to patients negative to both.
Experience the freedom of treating your RA patients every 6 months with MabThera.
Repeat MabThera treatment maintains or improves disease control over time.
MabThera is well tolerated and rates of serious infection remain consistent over repeat courses.
MabThera offers patients greater clinical effectiveness compared with an alternative TNF inhibitor.
MabThera is a unique B cell targeted therapy that provides a fundamentally different approach to the treatment of RA.
Quick links to useful resources in this website.
- Find out what makes MabThera® different from other RA treatments
- Download royalty free RA related photographs for use in PowerPoint presentations
- Learn more about MabThera® as a targeted therapy for seropositive patients
- Read a selection of interactive real life MabThera® case studies in the Virtual Clinic
Welcome to MabThera-RA.com
This website is designed to provide an extensive resource for non-US healthcare professionals involved in the management of patients with rheumatoid arthritis (RA).
MabThera-RA.com contains the following sections specifically designed to help you.
- About MabThera®: includes a wealth of clinical data relating to the mode of action, efficacy, safety and tolerability of MabThera®.
- Resources: features MabThera information you can download including information for new patients.
MabThera®, the first and only selective B cell therapy for RA, represents an innovative treatment option for RA patients and offers lasting treatment success. MabThera®, in combination with methotrexate, is indicated for the treatment of adult patients with severe, active RA who have had an inadequate response or intolerance to current treatment options, including one or more TNF inhibitors.